LONDON, May 4, 2017
/PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the
global medical technology business, welcomes the publication
of a new research paper showing how pressure ulcers, when treated
with Collagenase SANTYL Ointment, achieve faster rates of
granulation and epithelialization when compared against
medicinal honey treatment. Granulation is the process in which
new connective tissue and capillaries form around the edges of a
wound while epithelialization is the regrowth of skin over an open
wound.
In a retrospective study of 787 patients, those who received
SANTYL treatment on 1034 pressure ulcers were 38% more likely to
achieve 100% granulation, and 47% more likely to achieve
epithelialization at one year when compared to medicinal honey
treatment.
In addition, those patients treated with SANTYL had
significantly fewer hospital outpatient visits (9.1 "vs." 12.6;
p<0.001), fewer total selective sharp debridements (2.7 "vs."
4.4; p<0.001), and fewer pressure ulcers requiring NPWT (29%
"vs.' 38%; p=0.002).
The retrospective database analysis was conducted on
deidentified hospital outpatient wound clinic electronic health
records from 2007 to 2013 extracted from the US Wound Registry, and
published in the journal Advances in Wound Care.
Gilligan, A.M., et al. Comparative effectiveness of Clostridial
Collagenase Ointment to medicinal honey for treatment of pressure
ulcers. Volume 6, Number 4 (April
2017).
Collagenase SANTYL Ointment is the only FDA-approved enzymatic
debrider. SANTYL actively and selectively removes necrotic tissue
without harming granulation tissue. SANTYL is indicated for
debriding chronic dermal ulcers and severely burned areas. SANTYL
is a topical biologic agent that has a unique mechanism of action
and has been shown in other studies to help reduce the overall cost
of treating chronic wounds. Use of SANTYL should be terminated when
debridement of necrotic tissue is complete and granulation tissue
is established. SANTYL is supported by years of multiple clinical
trials that have underscored its efficacy. These clinical studies
support the use of SANTYL Ointment as a first-line debridement both
in between weekly sharp debridements and as a stand-alone
product.
"This research adds to the body of knowledge of the
effectiveness of SANTYL in a myriad of topical interventions
available to wound management clinicians," said Cathy Milne, APRN, MSN, BC, CWOCN of Connecticut
Clinical Nursing Associates. "Gilligan's work underscores the
importance of granulation and epithelialization in advancing
pressure ulcers through the healing
process."
"Pressure ulcers are a significant burden to patients and the
healthcare system," said Andy
Weymann, MD, Chief Medical Officer at Smith & Nephew.
"We are committed to reduce the financial and emotional costs
of living with pressure ulcers and this new research, using
real-world, electronic health record data, demonstrates SANTYL is
the better choice for helping patients with pressure ulcers."
About Smith & Nephew
Smith & Nephew is a
global medical technology business dedicated to helping healthcare
professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew has
around 15,000 employees and a presence in more than 100 countries.
Annual sales in 2015 were more than $4.6
billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
©2017 Smith & Nephew, All rights reserved.
SANTYL is a registered trademark of Smith & Nephew.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/collagenase-santyl-ointment-advances-pressure-ulcers-through-the-healing-process-faster-new-study-suggests-300450973.html
SOURCE Smith & Nephew